Wall Street analyst estimates for Ensysce Biosciences, Inc. (ENSC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.19 | ||
| 2026-08-13 | $-0.20 | $-0.20 | +0.0% |
| 2026-05-15 | $-0.52 | $-0.73 | +28.8% |
| 2026-03-30 | $-0.75 | $-1.26 | +40.5% |
| 2025-11-14 | $-1.29 | $-0.85 | -51.8% |
| 2025-08-13 | $-0.79 | $-1.02 | +22.5% |
| 2025-05-13 | $-1.39 | $-3.02 | +54.0% |
| 2025-03-19 | $-2.90 | $-2.74 | -5.8% |
Valuation Ratios
| Price / Book | -7.69 |
| EV / EBITDA | 0.16 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $1.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | $1.6M | $3.4M | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -$1.6M | -$1.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | 0 | 0 | $3.4M | $4.4M | $4.7M | $19.8M | $7.6M | $7.2M | $10.4M |
| Selling, General & Admin | $146695 | 0 | $6.9M | $1.2M | $18.7M | $6.9M | $5.4M | $4.7M | $4.9M |
| Operating Expenses | $146695 | -$600000 | $6.9M | $1.6M | $19.9M | $24.2M | $10.7M | $6.7M | $10.2M |
| Operating Income | -$147000 | -$959000 | -$8.6M | -$1.6M | -$19.9M | -$24.2M | -$10.7M | -$6.7M | -$10.2M |
| EBITDA | -$27555 | $2.7M | -$8.6M | -$1.6M | -$27.9M | -$24.1M | -$10.3M | -$6.7M | -$10.2M |
| Interest Expense | 0 | 0 | 0 | $995496 | $1.3M | $109525 | $353945 | $1.3M | $18767 |
| Pre-tax Income | -$27558 | $2.7M | -$10.1M | -$160875 | -$29.1M | -$24.2M | -$10.6M | -$8.0M | -$10.2M |
| Income Tax | $3635 | $553916 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$31193 | -$1.3M | -$10.1M | $56770 | -$29.1M | -$24.2M | -$10.6M | -$8.0M | -$10.2M |
| EPS | $-0.01 | $-0.22 | $-1.66 | $0.56 | $-355.68 | $-139.44 | $-4.69 | $-4.57 | $-3.98 |
| EPS (Diluted) | $-0.01 | $-0.22 | $-1.66 | $0.56 | $-355.68 | $-139.44 | $-4.69 | $-4.57 | $-3.98 |
| Shares Outstanding (Diluted) | $6.0M | $6.0M | $6.1M | $6.4M | $84018 | $179932 | $2.3M | $1.7M | $25.6M |
Price
| Price | $0.45 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AIM · CANF · KALA · KZIA · OGEN · QLGN · SNGX
Explore sector: Healthcare · Biotechnology
More sections of ENSC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks